Selected Resources

For Care Providers


AIDS Education Training Center (AETC):

Northeast/Caribbean AETC

Resource Library

Centers for Disease Control and Prevention (CDC): PrEP Resources for Care Providers Salzburg Statement on Shared Decision Making

New York City DOHMH: Making the Sexual History a Routine Part of Primary Care

New York State Department of Health (NYSDOH):

CEI: HIV, HCV & STD Clinical Education Initiative

CEI: PEP, PrEP, and HCV Clinical Cards (to attach to name badges; available for NYS care providers)

Emergency Contraception: What You Need to Know

NYS AIDS Institute Training Center

Partner Services: What Health Care Providers Need to Know

PrEP and PEP Information & Resources

Provider Reporting & Partner Services

Sexually Transmitted Diseases

University of California San Francisco (UCSF): PrEP for U.S. Trans Women



CDC: PrEP Clinical Practice Guideline 2014




Communicable Disease Reporting Requirements

Expedited Partner Therapy: A Guide for Partner Care

HIPAA Information Center

HIV Testing

Informed Consent for HIV Testing and Access to HIV Care for Adolescents

HIV/AIDS Testing, Reporting and Confidentiality of HIV-Related Information

New York State PrEP/PEP Provider Voluntary Director

Partner Services: What Health Care Providers Need to Know

PrEP and PEP Information & Resources

Provider Reporting & Partner Services



New York eHealth Collaborative: NYEC


CEI: HIV, HCV & STD Clinical Education Initiative

Directory of ESAP Providers in New York State

Expanded HIV Testing website

Expanded Syringe Access Program (ESAP): Overview of Law and Regulations

HIPAA Information Center

HIV Testing

New York State PrEP/PEP Provider Voluntary Director

Partner Services: What Health Care Providers Need to Know

PrEP and PEP Information & Resources

Provider Reporting & Partner Services

Sexually Transmitted Diseases

STD Clinics in New York State

Wadsworth Center

UCSF Clinician Consultation Center

Pre-Exposure Prophylaxis

Phone Consultation: 855-448-7737 (M-F, 11am-6pm EST)



AIDSinfo: Drug Database

HIV Clinical Resource:

Mental Health Screening: Quick Ref Guide

Payment Options for PrEP

Provider Guide to HIV Testing

Substance Use Screening: Quick Reference Guide

NYSDOH: CEI: HIV, HCV & STD Clinical Education Initiative

University of Liverpool: HIV Drug Interactions

UCSF HIV InSite: Database of Antiretroviral Drug Interactions

PrEP Payment Options

April 2016

Type Coverage or Services Eligibility Contacts
Private Insurance

Most plans cover PrEP

Coverage varies based on plan, and there may be deductibles and co-payments

Medicaid PrEP prescription costs, medical appointments, and lab tests Prior approval that must be renewed every 3 months

HELPLINE: (800) 541-2831


PrEP Assistance Program (PrEP-AP)

Doctors’ visits and lab tests

HIV and STI/STD testing, counseling, and supportive primary care services consistent with PrEP clinical guidelines

PrEP medications obtained through manufacturer patient assistance programs 

There is no age limitation, but to be eligible, a patient must be: 1) Not HIV-infected; 2) At risk acquiring of HIV; 3) A resident of New York State; 4) Uninsured or under-insured; 5) At 435% of the Federal Poverty Level (FPL) or lower with annual income

To be eligible, providers must be: 1) Enrolled in the New York State Medicaid Program; and 2) Responsible for assisting patients with the PAP application to receive Truvada as indicated for PrEP

HOTLINE: (800) 542-2437

ADAP Provider Relations: (518) 459-1641 or e-mail 

Gilead Co-Pay Coupon Card  Up to $300/month in prescription co-payments To be eligible, patients must: 1) Be 18 years of age or older; 2) Have private insurance; 3) NOT be enrolled in Medicare or Medicaid

Phone: (877) 505-6986


Gilead Truvada for PrEP Medication Assistance Program Prescription costs To be eligible, patients must: 1) Be uninsured or have no insurance coverage for prescription medications; 2) Have an annual income less than 500% of FPL

Phone: (855) 330-5479


Patient Advocate Foundation for Co-Pay Relief

Grants of up to $7,500 per year for assistance with co-payments, co-insurance, and deductibles

There is no age limitation, but to be eligible, patients must: 1) Have insurance and coverage for prescription medications; 2) Have an annual income less than 400% of FPL


Phone: (866) 512-3861

Applications may be submitted online or by by phone: (866) 512-3861, M-F 8:30 AM to 5:30 PM, EST, by patients or by their medical care provider or pharmacist

Partnership for
Prescription Assistance
(PPA) Program

Helps uninsured Americans get prescription medications at no or low cost


Visit the website, enter drug names, and answer a few questions to learn of available options

Phone: (888) 477-2669


Gilead Advancing Access

Matches patients to a Gilead assistance program based on eligibility criteria


Phone: (800) 226-2056 Counselors are available M-F,
9 am to 8 pm EST; confidential messages may be left at any time



Q/A: PrEP to Prevent HIV Infection

January 2013

In July 2012 the U.S. Food and Drug Administration (FDA) approved the first use of an antiretroviral drug to prevent HIV infection. Truvada, a combination of two HIV medications, can now be used by persons who are HIV-negative to protect them from possible infection.

The following questions and answers are meant to educate consumers on PrEP and whether it is right for them.

What is Pre-Exposure Prophylaxis (PrEP)? A prophylactic is a drug you take to prevent disease. When you take a drug to prevent HIV infection, it is called HIV prophylaxis. With post-exposure prophylaxis (PEP), you take an HIV medication immediately AFTER the exposure to HIV to prevent infection. With PrEP, if you are HIV-negative, you take Truvada BEFORE possible exposure to HIV to prevent infection. Truvada is a combination of the drugs Emtriva and Viread. It was originally approved for treatment in 2004.

What does the new FDA approval of PrEP mean? Recent research studies confirmed that Truvada safely and effectively prevented HIV infection among HIV-negative men who have sex with men (MSM) and transgender women who have sex with men. Both groups were considered to be at high risk of infection. Based on the research findings, the FDA approved the use of PrEP for these two groups.

Further research found that Truvada is also safe and effective at preventing HIV infection among heterosexual men and women. These include serodiscordant couples, where one partner is HIV-positive and the other is HIV-negative. In July 2012, the FDA approved the use of PrEP for sexually active heterosexual men and women. The U.S. Public Health Service will soon issue complete guidelines on the use of PrEP. In the meantime, providers should rely on the CDC “interim guidance” for prescribing PrEP (see link below).

Why did the FDA approve an HIV drug for people who don’t have HIV? HIV medications and better medical care have helped many HIV-positive people regain their health, so that fewer people are progressing to AIDS and dying. However, nearly 50,000 people in the U.S. still get infected with HIV each year. Because the number of new infections has stayed constant in recent years, public health officials are looking for new and different ways to prevent infection.

Using a preventive medication before exposure to a virus is not new. For example, people who travel to countries where malaria is a problem often take medications beforehand to protect them from being infected by mosquitoes.

What are the guidelines/requirements for providers to prescribe PrEP?

  • You must be HIV-negative.
  • You cannot have “flu-like” symptoms, which may indicate you have acute HIV phase, the earliest stage of infection.
  • Practice other forms of risk-reduction: use condoms; get tested for HIV regularly; don’t share drug injection equipment; get risk-reduction counseling; and get screened for STDs and hepatitis B.
  • Stick to your HIV medication schedule. Take all your meds on time, as prescribed. Very few participants in the PrEP clinical trials developed resistance to the medications, even if they became infected with HIV. The researchers concluded that, if HIV-negative patients are monitored closely, the benefits of PrEP outweighed the risks connected with drug resistance.

How will my healthcare provider decide whether PrEP is right for me? This will depend on a number of factors:

If you are a man who has sex with men, your healthcare provider must first confirm that you are HIV-negative and that you have no current (flu-like) symptoms of acute HIV. Your provider will also test you for hepatitis B infection, for STDs, and for kidney function. Your provider has to conclude that you are at ongoing, high risk for HIV infection because of behaviors such as unprotected sex, needle sharing, or drug and alcohol use. Your provider will also consider how well you can stick with a PrEP medication schedule despite your risk behaviors.

If you are a heterosexual male or female, and a sexually active heterosexual adult who is HIV-negative, your provider can prescribe PrEP if you are at “very high risk” of getting HIV from penile-vaginal sex. This situation may occur if your partner is HIV-positive. Again, PrEP must be part of a larger effort to prevent HIV transmission. Your provider will talk to you about reducing your risk of infection, getting tested and treated for STDs, and taking your PrEP medications as prescribed.

Does PrEP have significant side effects? The main side effects felt by the patients in the PrEP clinical trials were mild nausea and problems with kidney function. Everyone who takes PrEP should see their medical provider for kidney function tests every six months.

Is PrEP safe for pregnant or breastfeeding women? Pregnant and breastfeeding women were not included in the PrEP research studies — so the safety and efficacy of Truvada for pregnant women and fetuses/infants has not been established. Women of child-bearing age should have a pregnancy test before beginning PrEP and at regular intervals while taking PrEP. If you are pregnant before starting PrEP or want to become pregnant while taking PrEP, talk with your healthcare provider about the risks and benefits.

The two drugs contained in Truvada have been used safely and effectively to prevent HIV transmission from mother to child — there was no harm to infants exposed to PrEP.

How much does PrEP cost? Is it covered by insurance? Truvada, the PrEP drug, costs between $8,000 and $14,000 per year. You will also have to figure in the cost of four medical check-ups annually and possible lab tests. Check with your medical insurer to see if PrEP is covered.

Where can I learn more?

  • CDC Interim Guidance for using PrEP with MSM
  • CDC Interim Guidance for using PrEP with heterosexuals
  • CDC PrEP Information Sheet for both MSM and heterosexuals
  • Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399–410. [PubMed]
  • Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423–34. [PubMed]
  • Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367:411–22. [PubMed]
  • Mugo NR, Heffron R, Donnell D, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS 2011;25:1887–95. [PubMed]
  • Lampe MA, Smith DK, Anderson GJE, Edwards AE, Nesheim SR. Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol 2011;204:488. [PubMed]